紫杉醇双途径给药联合替吉奥及阿帕替尼治疗老年胃癌伴腹膜转移的临床分析  

Clinical analysis of dual pathway administration of paclitaxel combined with tegafur and apatinib in the treatment of gastric cancer complicated with peritoneal metastasis in elderly patients

作　　者：谢晓东[1] 杨绪亮 赵鸿鹰 姜海英[1] 朱梅[1] Xie Xiaodong;Yang Xuliang;Zhao Hongying;Jiang Haiying;Zhu Mei(Department of Oncology,Cancer Hospital of Xuzhou City,Xuzhou,Jiangsu,221005,P.R.China;Department of Gastrointestinal Surgery,Cancer Hospital of Xuzhou City,Xuzhou,Jiangsu,221005,P.R.China)

机构地区：[1]徐州市肿瘤医院肿瘤内科,江苏徐州221005 [2]徐州市肿瘤医院胃肠外科,江苏徐州221005

出　　处：《老年医学与保健》2023年第4期726-731,共6页Geriatrics & Health Care

基　　金：江苏省健康委员会2022年度医学科研项目(Z2020097)。

摘　　要：目的探讨在老年胃癌伴腹膜转移(P1CY1)患者中应用紫杉醇双途径给药联合替吉奥及阿帕替尼转化治疗的作用,为治疗该病症提供方法。方法回顾性分析徐州市肿瘤医院2018年6月—2020年6月收治的老年胃癌伴腹膜转移患者的病例资料,根据样本量计算共纳入78例,其中采用紫杉醇静脉化疗联合替吉奥、阿帕替尼治疗的患者设为对照组(39例),采用紫杉醇腹腔灌注+静脉注射双途径给药联合替吉奥、阿帕替尼治疗的患者设为观察组(39例)。观察并比较2组的临床疗效、手术切除患者的化疗周期、治疗前后的体能状态、治疗期间的不良反应发生情况及随访生存情况。结果观察组治疗后客观缓解率(ORR)、疾病控制率(DCR)、手术切除率均明显高于对照组(P<0.05);观察组中行手术切除患者平均化疗周期短于对照组(P<0.05);2组治疗后KPS评分均高于同组治疗前,且观察组KPS评分高于对照组(P<0.05);观察组治疗后总血液不良反应发生率和非血液不良反应发生率虽低于对照组,但差异均无统计学意义(P>0.05);随访2年,观察组的PFS和OS均长于对照组(P<0.05)。结论紫杉醇双途径给药联合替吉奥及阿帕替治疗老年胃癌伴腹膜转移患者的效果较好,患者的生存时间延长,治疗不良反应没有明显增加,具有一定的应用价值。Objective To explore the effect of dual pathway administration of paclitaxel combined with tegafur and apa⁃tinib conversion therapy in elderly patients with gastric cancer complicated with peritoneal metastasis(P1CY1),and provide a method for the treatment of this disease.Methods The case data of elderly patients with gastric cancer complicated with peri⁃toneal metastasis admitted to Cancer Hospital of Xuzhou City from June 2018 to June 2020 were retrospectively analyzed.A to⁃tal of 78 cases were included according to the sample size calculation.Among them,patients treated with paclitaxel intravenous chemotherapy combined with tegafur and apatinib were set as the control group(39 cases),while patients treated with paclitax⁃el intraperitoneal perfusion+intravenous injection combined with tegafur and apatinib were set as the observation group(39 ca⁃ses).The clinical efficacy,chemotherapy cycle of the patients undergoing surgical resection,physical condition before and af⁃ter treatment,incidence of adverse reactions during treatment,and survival condition during follow⁃up of the two groups were observed and compared.Results The objective remission rate(ORR),disease control rate(DCR)and surgical resection rate in the observation group were significantly higher than those in the control group(P<0.05).The mean chemotherapy cycle of patients undergoing surgical resection in the observation group was shorter than that in the control group(P<0.05).After treatment,the KPS scores of both groups were higher than those of the same group before treatment,and the KPS scores of the observation group were higher than those of the control group(P<0.05).The total incidence of blood adverse reactions and non⁃blood adverse reactions after treatment in the observation group was lower than that in the control group,but there was no statistical significance(P>0.05).After 2 years of follow⁃up,PFS and OS of the observation group were longer than those of the control group(P<0.05).Conclusion The dual pathway administratio

关 键 词：胃癌 老年 腹膜转移 腹腔灌注:紫杉醇 替吉奥 阿帕替尼 

分 类 号：R735.2[医药卫生—肿瘤]